Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference 2025. The company's CEO, Dr. Shawn Leland, will engage in a fireside chat on Tuesday, March 11, 2025, at 2:20 p.m. EDT.
Investors and interested parties can access a live webcast of the presentation through Affimed's website investor section. The presentation recording will remain available for 30 days following the event. For those interested in one-on-one meetings with Affimed's management team, arrangements can be made through Leerink Partners representatives or by contacting Alex Fudukidis.
Affimed N.V. (Nasdaq: AFMD), un'azienda di immuno-oncologia in fase clinica, ha annunciato la sua partecipazione alla prossima Conferenza Globale sulla Salute di Leerink Partners 2025. L'amministratore delegato dell'azienda, Dr. Shawn Leland, parteciperà a un colloquio informale il martedì 11 marzo 2025, alle 14:20 EDT.
Gli investitori e le parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso la sezione per investitori del sito web di Affimed. La registrazione della presentazione rimarrà disponibile per 30 giorni dopo l'evento. Per coloro che sono interessati a incontri individuali con il team di gestione di Affimed, è possibile organizzare appuntamenti tramite i rappresentanti di Leerink Partners o contattando Alex Fudukidis.
Affimed N.V. (Nasdaq: AFMD), una empresa de inmuno-oncología en etapa clínica, ha anunciado su participación en la próxima Conferencia Global de Salud de Leerink Partners 2025. El CEO de la compañía, Dr. Shawn Leland, participará en una charla informal el martes 11 de marzo de 2025, a las 2:20 p.m. EDT.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección para inversores del sitio web de Affimed. La grabación de la presentación estará disponible durante 30 días después del evento. Para aquellos interesados en reuniones uno a uno con el equipo de gestión de Affimed, se pueden hacer arreglos a través de los representantes de Leerink Partners o contactando a Alex Fudukidis.
Affimed N.V. (Nasdaq: AFMD), 임상 단계의 면역 종양학 회사가 다가오는 Leerink Partners 글로벌 헬스케어 컨퍼런스 2025에 참여한다고 발표했습니다. 회사의 CEO인 Dr. Shawn Leland는 2025년 3월 11일 화요일 오후 2시 20분 EDT에 대화 형식의 세션에 참여할 예정입니다.
투자자 및 관심 있는 분들은 Affimed 웹사이트의 투자자 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 발표 녹화는 이벤트 후 30일 동안 이용 가능합니다. Affimed 경영진과의 일대일 미팅에 관심이 있는 분들은 Leerink Partners의 대표를 통해 또는 Alex Fudukidis에게 연락하여 조정을 할 수 있습니다.
Affimed N.V. (Nasdaq: AFMD), une entreprise d'immuno-oncologie en phase clinique, a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé de Leerink Partners 2025. Le PDG de l'entreprise, Dr. Shawn Leland, participera à une discussion informelle le mardi 11 mars 2025, à 14h20 EDT.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section investisseurs du site web d'Affimed. L'enregistrement de la présentation restera disponible pendant 30 jours après l'événement. Pour ceux qui s'intéressent à des réunions en tête-à-tête avec l'équipe de direction d'Affimed, des arrangements peuvent être pris par l'intermédiaire des représentants de Leerink Partners ou en contactant Alex Fudukidis.
Affimed N.V. (Nasdaq: AFMD), ein Unternehmen für Immunonkologie in der klinischen Phase, hat seine Teilnahme an der bevorstehenden Leerink Partners Global Healthcare Conference 2025 angekündigt. Der CEO des Unternehmens, Dr. Shawn Leland, wird am Dienstag, den 11. März 2025, um 14:20 Uhr EDT an einem informellen Gespräch teilnehmen.
Investoren und Interessierte können über den Investorenbereich der Website von Affimed auf einen Live-Stream der Präsentation zugreifen. Die Aufzeichnung der Präsentation bleibt 30 Tage nach der Veranstaltung verfügbar. Für diejenigen, die an persönlichen Meetings mit dem Management-Team von Affimed interessiert sind, können Arrangements über die Vertreter von Leerink Partners oder durch Kontaktaufnahme mit Alex Fudukidis getroffen werden.
- None.
- None.
MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Shawn Leland, PharmD, RPh, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 at 2:20 p.m. Eastern Daylight Time.
A live webcast of the presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed’s website for 30 days after the call.
For more information on the conference or to schedule a one-on-one meeting with Affimed’s management, please contact your Leerink Partners representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Investor Relations
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
FAQ
When is Affimed (AFMD) presenting at the Leerink Partners Healthcare Conference 2025?
How can investors watch Affimed's (AFMD) presentation at the Leerink Conference?
How long will Affimed's (AFMD) Leerink Conference presentation replay be available?
How can investors schedule one-on-one meetings with Affimed's (AFMD) management at the Leerink Conference?
